在一篇“Perspectives”評論文章中，Johann de Bono 和 Alan Ashworth對當(dāng)前癌癥臨床試驗方面的相關(guān)程序做了批評性的審視,?？拱┧幬镩_發(fā)方面的重點目前被堅定地放在以分子為目標(biāo)的、合理設(shè)計的藥物上,，而不是放在非特異性細胞毒素上,。
然而，盡管取得了一些成功,，但很多癌癥（如胰腺癌和肺癌）的預(yù)后仍然較差,。很多試驗對于患者的治療效果或我們對癌癥生物學(xué)的認識影響都很小，而只是獲得對于一般患者而非對于任何一位具體患者來說的某種最佳療法,。de Bono 和Ashworth認為應(yīng)當(dāng)采取一種新方式,，該方式涉及將癌癥研究與由生物標(biāo)記驅(qū)動的自適應(yīng)臨床試驗和以驗證假設(shè)為目的的臨床試驗結(jié)合起來。（生物谷Bioon.com）
>>>借著上海世博會的良好契機,，"第一屆腫瘤基礎(chǔ)和轉(zhuǎn)化醫(yī)學(xué)國際研討會"將于2010年10月12日在中國上海盛大開幕,，這將為廣大活躍在腫瘤基礎(chǔ)和轉(zhuǎn)化醫(yī)學(xué)第一線的科研工作者提供一個互動交流的平臺。
會議官方網(wǎng)站：www.cancerasia.org
生物谷推薦英文摘要：
Nature doi:10.1038/nature09339
Translating cancer research into targeted therapeutics
J. S. de Bono& Alan Ashworth
The emphasis in cancer drug development has shifted from cytotoxic, non-specific chemotherapies to molecularly targeted, rationally designed drugs promising greater efficacy and less side effects. Nevertheless, despite some successes drug development remains painfully slow. Here, we highlight the issues involved and suggest ways in which this process can be improved and expedited. We envision an increasing shift to integrated cancer research and biomarker-driven adaptive and hypothesis testing clinical trials. The goal is the development of specific cancer medicines to treat the individual patient, with treatment selection being driven by a detailed understanding of the genetics and biology of the patient and their cancer.
